Sign inJoin waitlistJoin the waitlist

Susan Prockop

Head, Clinical Research Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center · Stanford Health Care

Credentials: · · ·

History

Clinical Research Stem Cell Transplantation and Cellular Therapies Service Division · Stanford Health Care
Present
Mass General Brigham
Present

Memorial Sloan Kettering Cancer Center
1996–1997
Babies and Children's Hospital
1993–1996
Columbia Univ Coll of Phys & Surgeons
1989–1993

Research

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Blood · 2012 · 345 citations
Mapping precursor movement through the postnatal thymus reveals specific microenvironments supporting defined stages of early lymphoid development
The Journal of Experimental Medicine · 2001 · 263 citations
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Blood · 2019 · 238 citations

Richard O’Reilly
58 papers
NK
Nancy Kernan
40 papers
FB
Farid Boulad
38 papers
AS
Andromachi Scaradavou
32 papers
JB
Jaap-Jan Boelens
30 papers
MP
Miguel-Angel Perales
22 papers
KC
Kevin Curran
19 papers
Luigi Notarangelo
18 papers
Sung-Yun Pai
18 papers
Christopher Dvorak
17 papers
Morton Cowan
17 papers
NK
Neena Kapoor
17 papers

Grants

Damage to Thymic Stroma & de novo T Cell Production.
National Institute of Allergy and Infectious Diseases · K08
Contact PI · $483.5K · Sloan-Kettering Inst Can Research
2003–2008

Clinical trials

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies
Principal investigator · Withdrawn · Phase 2
Memorial Sloan Kettering Cancer Center
2019–2020
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors
Principal investigator · Terminated
Memorial Sloan Kettering Cancer Center
2017–2021
JSP191 Antibody Targeting Conditioning in SCID Patients
Principal investigator · Terminated · Phase 1, Phase 2
Jasper Therapeutics, Inc.
2017–2025
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2014–2024